TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38383462

Group type: EXPERIMENTAL
Intervention: Liraglutide (daily injections for at least 13 weeks before and 52 weeks after AF ablation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study: 38383459

Group type: EXPERIMENTAL
Intervention: Shoulder exercise with pain allowed
Number of subjects: 84

Group type: COMPARATOR
Intervention: Shoulder exercise with pain avoided
Number of subjects: 84
Study: 38383476

Group type: EXPERIMENTAL
Intervention: Low-sodium bread (280 mg Na/100 g) in Group C
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard bread (750 mg Na/100 g) in Group A
Number of subjects: 57

Group type: COMPARATOR
Intervention: Low-sodium diet with standard bread in Group B
Number of subjects: 57
Study: 38383530

Group type: EXPERIMENTAL
Intervention: Robot-assisted partial knee arthroplasty
Number of subjects: 64

Group type: COMPARATOR
Intervention: Manual total knee arthroplasty
Number of subjects: 64
Study: 38383578

Group type: EXPERIMENTAL
Intervention: AKS-452 (90 µg subcutaneous booster dose)
Number of subjects: 71
Study: 38383794

Group type: EXPERIMENTAL
Intervention: Step-reduction to <2000 steps for 2 weeks followed by 4 weeks of exercise rehabilitation 4 times per week
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group continued habitual physical activity with no additional exercise intervention
Number of subjects: 66
Study: 38383961

Group type: EXPERIMENTAL
Intervention: Daprodustat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38384122

Group type: EXPERIMENTAL
Intervention: Four Square Step Test (FSST) under dual-task (DT) conditions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Timed Up and Go (TUG) under single-task condition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hospital for Special Surgery (HSS) Knee Score
Number of subjects: 30
Study: 38384123

Group type: COMPARATOR
Intervention: Radial shockwave therapy (RSWT) - five treatments (one week apart over five-week period) to the three most painful areas (500 shocks at 1.5 bar and 15 Hz, then 1000 shocks at 2 bar and 8 Hz, and finally 500 shocks at 1.5 bar and 15 Hz)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 0
Study: 38384142

Group type: EXPERIMENTAL
Intervention: Diabetes Distress Scale (four domains: regimen, emotional, interpersonal, healthcare provider)
Number of subjects: 0
Study: 38384179

Group type: EXPERIMENTAL
Intervention: Inflamed tissue obtained from the most active lesion
Number of subjects: 47

Group type: COMPARATOR
Intervention: Uninflamed tissue collected from approximately 15 cm above the upper end of the active lesion
Number of subjects: 47
Study: 38384245

Group type: EXPERIMENTAL
Intervention: AAV-mediated gene therapy for genetic diseases
Number of subjects: 400000000

Group type: EXPERIMENTAL
Intervention: Gene therapy products
Number of subjects: 400000000
Study: 38384289

Group type: EXPERIMENTAL
Intervention: Hexasodium fytate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38384338

Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 357

Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Vortioxetine and SSRIs
Number of subjects: 357
Study: 38384348

Group type: EXPERIMENTAL
Intervention: TAU + CT
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TAU + M4H
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TAU + MCT
Number of subjects: 120

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 120
Study: 38384390

Group type: EXPERIMENTAL
Intervention: Exposure-based therapy (EXP)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Behavioral activation (BA)
Number of subjects: 102
Study: 38384458

Group type: EXPERIMENTAL
Intervention: Intracranial infusion of TMZ-resistant γδ T cells (genetically engineered with p140K/MGMT lentivector)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard regimen of Temozolomide (TMZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug Resistance Immunotherapy (DRI) combining TMZ and TMZ-resistant γδ T cells
Number of subjects: 0
Study: 38384801

Group type: EXPERIMENTAL
Intervention: UV1 vaccination in combination with pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pembrolizumab as a single agent
Number of subjects: 0
Study: 38384879

Group type: EXPERIMENTAL
Intervention: Education and strategies for self-managing symptoms of Long COVID (PASC)
Number of subjects: 0
Study: 38384923

Group type: EXPERIMENTAL
Intervention: Innovation Lab (week-long immersive collaboration experience)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 95
Study: 38385031

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 positive individuals
Number of subjects: 404

Group type: COMPARATOR
Intervention: SARS-CoV-2 negative individuals
Number of subjects: 404
Study: 38385137

Group type: EXPERIMENTAL
Intervention: C-ESWT (200 shots/spot at 0.09 mJ/mm²)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study: 38385243

Group type: EXPERIMENTAL
Intervention: Chlorambucil plus subcutaneous rituximab induction and maintenance
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab maintenance
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Chlorambucil plus rituximab (induction phase)
Number of subjects: 112
Study: 38385529

Group type: EXPERIMENTAL
Intervention: Pentaspline pulsed-field ablation catheter
Number of subjects: 179
Study: 38385566

Group type: EXPERIMENTAL
Intervention: mRNA-1345 (12.5, 25, 50, 100, or 200 µg)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: mRNA-1345 (first injection)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: mRNA-1345 (12-month booster)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 38385587

Group type: COMPARATOR
Intervention: Fenofibrate (145 mg tablet daily or on alternate days for those with impaired renal function)
Number of subjects: 1151
Study: 38385922

Group type: EXPERIMENTAL
Intervention: Tendyne transcatheter mitral valve replacement (TMVR)
Number of subjects: 195
Study: 38385926

Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 426
Study: 38385941

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 448

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study: 38386005

Group type: EXPERIMENTAL
Intervention: Race-specific equations in pulmonary function tests
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pulmonary function tests
Number of subjects: 0
Study: 38386030

Group type: EXPERIMENTAL
Intervention: Modified HEMSTOP score including gingival bleeding
Number of subjects: 117

Group type: COMPARATOR
Intervention: HEMSTOP score without gingival bleeding
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Gingival bleeding
Number of subjects: 117
Study: 38386029

Group type: EXPERIMENTAL
Intervention: Fat Mass Index (FMI)
Number of subjects: 1422

Group type: COMPARATOR
Intervention: Body Mass Index (BMI)
Number of subjects: 1422
Study: 38386051

Group type: EXPERIMENTAL
Intervention: Neurospeed semi-compliant balloon
Number of subjects: 8
Study: 38386178

Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg every 4 weeks (Q4W)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg every 8 weeks (Q8W)
Number of subjects: 739

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: guselkumab (Q4W and Q8W)
Number of subjects: 739
Study: 38386180

Group type: EXPERIMENTAL
Intervention: Silicone oil removal
Number of subjects: 30
Study: 38386266

Group type: EXPERIMENTAL
Intervention: Preoperative 1 mg dexamethasone suppression test
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Presence of diabetes
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ACTH levels
Number of subjects: 32
Study: 38386322

Group type: EXPERIMENTAL
Intervention: Communities That HEAL (CTH) intervention
Number of subjects: 8166963

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 8166963
Study: 38386376

Group type: EXPERIMENTAL
Intervention: eHealth platform for cardiac rehabilitation
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Support for regular physical exercise
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Availability of information on diagnosis, current medication, test results, and risk scores
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Individualized care support
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Acceptance of eHealth components
Number of subjects: 79
Study: 38386396

Group type: EXPERIMENTAL
Intervention: Social media intervention promoting guideline-related goals for increased physical activity, healthy eating, HPV vaccination, and reduced nicotine product use, alcohol intake, and solar UV radiation exposure, delivered over 12 months in Facebook private groups.
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Social media intervention
Number of subjects: 1000
Study: 38386434

Group type: EXPERIMENTAL
Intervention: Community-Derived Open-Source Automated Insulin Delivery Loop System
Number of subjects: 0
Study: 38386438

Group type: EXPERIMENTAL
Intervention: Insulin Glargine 300 U/mL
Number of subjects: 0
Study: 38386436

Group type: EXPERIMENTAL
Intervention: Clock-Based Nocturnal Hypoglycemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypoglycemia While Asleep
Number of subjects: 0
Study: 38386505

Group type: EXPERIMENTAL
Intervention: Single intra-articular injection of GMP manufactured stromal vascular fraction (SVF)
Number of subjects: 29
Study: 38386795

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38386949

Group type: EXPERIMENTAL
Intervention: Zagotenemab 1,400 mg
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Zagotenemab 5,600 mg
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 38386978

Group type: EXPERIMENTAL
Intervention: rilzabrutinib 400 mg twice daily
Number of subjects: 16
Study: 38387470

Group type: EXPERIMENTAL
Intervention: Hepatitis E vaccine (three doses administered intramuscularly at month 0, month 1, and month 6)
Number of subjects: 112604

Group type: COMPARATOR
Intervention: Placebo (three doses administered intramuscularly at month 0, month 1, and month 6)
Number of subjects: 112604
Study: 38387597

Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) treatment applied once per week for 3 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment applied once per week for 3 weeks
Number of subjects: 40
Study: 38387646

Group type: EXPERIMENTAL
Intervention: Corticosteroids and itraconazole
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 132
Study: 38387980

Group type: EXPERIMENTAL
Intervention: Collaborative care model
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 38387978

Group type: EXPERIMENTAL
Intervention: High-frequency data collection and analysis techniques, novel clinical interventions, and comparative effectiveness methodology.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Data collection from ICU treatment for specific aspects of msTBI care.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Reports documenting performance on selected key quality indicators.
Number of subjects: 300
Study: 38387984

Group type: EXPERIMENTAL
Intervention: Long-term use of CNSDs
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Surviving users of CNSDs
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 246
Study: 38387985

Group type: EXPERIMENTAL
Intervention: Youth-centred Participatory Action (YoPA) project interventions
Number of subjects: 800
Study: 38387989

Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 144

Group type: COMPARATOR
Intervention: S/CPS
Number of subjects: 144
Study: 38388014

Group type: EXPERIMENTAL
Intervention: Active stimulation (auricular neuromodulation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study: 38388017

Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency (RF) treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional radiofrequency (RF) treatment
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cooled RF treatment in PPSP
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional RF treatment in PPSP
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cooled RF treatment in OA
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional RF treatment in OA
Number of subjects: 49
Study: 38388019

Group type: EXPERIMENTAL
Intervention: Active stimulation (n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation (n=15)
Number of subjects: 30
Study: 38388022

Group type: EXPERIMENTAL
Intervention: Smartphone game intervention for HIV prevention; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; details on intervention or control not available.
Number of subjects: 0
Study: 38388167

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus famitinib
Number of subjects: 41
Study: 38388171

Group type: EXPERIMENTAL
Intervention: Bimekizumab (160 mg every 4 weeks)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo/Bimekizumab (receiving bimekizumab from week 16 to 52)
Number of subjects: 400
Study: 38388189

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 38388236

Group type: EXPERIMENTAL
Intervention: Booster shot with Sabin inactivated poliomyelitis vaccine
Number of subjects: 1200
Study: 38388444

Group type: EXPERIMENTAL
Intervention: Lymphadenectomy with sealant Glubran 2®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lymphadenectomy without sealant (control group)
Number of subjects: 0
Study: 38388470

Group type: EXPERIMENTAL
Intervention: PIMSRA
Number of subjects: 27
Study: 38388489

Group type: EXPERIMENTAL
Intervention: Combined intervention (outdoor intervention + indoor air purification with HEPA filters)
Number of subjects: 182

Group type: COMPARATOR
Intervention: No intervention (controls)
Number of subjects: 182
Study: 38388571

Group type: EXPERIMENTAL
Intervention: Exercise with a lower-extremity powered exoskeleton (Exo) for 8 weeks, 2 times per week.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Exercise without a lower-extremity powered exoskeleton (Nxo) for 8 weeks, 2 times per week.
Number of subjects: 27
Study: 38388646

Group type: EXPERIMENTAL
Intervention: Subcutaneous cytarabine (100 mg/m2 for 5 days) administered in 35-day cycles for 12 total cycles
Number of subjects: 61
Study: 38388715

Group type: EXPERIMENTAL
Intervention: Increased social distancing (SDI)
Number of subjects: 0
Study: 38388986

Group type: EXPERIMENTAL
Intervention: RBP-7000 (180 mg monthly injections)
Number of subjects: 23
Study: 38388987

Group type: EXPERIMENTAL
Intervention: P11-4 varnish
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: NSF varnish
Number of subjects: 66

Group type: COMPARATOR
Intervention: NaF varnish
Number of subjects: 66
Study: 38389038

Group type: EXPERIMENTAL
Intervention: Travel distance > 60 km
Number of subjects: 1436

Group type: EXPERIMENTAL
Intervention: Travel distance median 40.96 km (IQR: 17.12, 63.49)
Number of subjects: 1436
Study: 38389050

Group type: EXPERIMENTAL
Intervention: Sustained Natural Apophyseal Glides (SNAGs)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Rocabado 6 × 6 program
Number of subjects: 38
Study: 38389078

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg once daily for 28 days (group A)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 220
Study: 38389113

Group type: EXPERIMENTAL
Intervention: 3D HD system
Number of subjects: 48

Group type: COMPARATOR
Intervention: 2D 4K system
Number of subjects: 48
Study: 38389458

Group type: EXPERIMENTAL
Intervention: Sexual Health Intervention for Men
Number of subjects: 90

Group type: COMPARATOR
Intervention: Referral and information control
Number of subjects: 90
Study: 38389469

Group type: EXPERIMENTAL
Intervention: DragonFly system for transcatheter valve repair
Number of subjects: 120
Study: 38389481

Group type: EXPERIMENTAL
Intervention: Tipping Point Program (TPP)
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Tipping Point Program Plus (TPP+)
Number of subjects: 1275

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1275
Study: 38389759

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 0
Study: 38389985

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Breathing-based yoga practice (Sudarshan Kriya Yoga; SKY)
Number of subjects: 85
Study: 38390383

Group type: EXPERIMENTAL
Intervention: KC@H programme (internet-based sessions of therapeutic exercises at home and conventional CR sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional clinic-based rehabilitation (CR)
Number of subjects: 0
Study: 38390395

Group type: EXPERIMENTAL
Intervention: hyperbaric spinal bupivacaine 0.5%, 1.3 ml (0.65 mg)
Number of subjects: 280
Study: 38390658

Group type: EXPERIMENTAL
Intervention: Primary RPL (two or more pregnancy losses before the first live birth)
Number of subjects: 184241

Group type: EXPERIMENTAL
Intervention: Secondary RPL (RPL patients with no or one pregnancy loss before the first live birth)
Number of subjects: 184241

Group type: COMPARATOR
Intervention: Individuals without RPL
Number of subjects: 184241

Group type: EXPERIMENTAL
Intervention: Pregnancy complications at first and second live births in patients with primary RPL
Number of subjects: 184241

Group type: EXPERIMENTAL
Intervention: Cumulative second live birth rates in patients with primary RPL
Number of subjects: 184241
Study: 38390793

Group type: EXPERIMENTAL
Intervention: Dapagliflozin added to standard of care
Number of subjects: 0
Study: 38390795

Group type: EXPERIMENTAL
Intervention: High plasma 4β-hydroxycholesterol (4βHC) concentration
Number of subjects: 1946

Group type: COMPARATOR
Intervention: Low plasma 4β-hydroxycholesterol (4βHC) concentration
Number of subjects: 1946
Study: 38390800

Group type: EXPERIMENTAL
Intervention: sST2, GDF-15, NT-proBNP (cardiac biomarkers)
Number of subjects: 566
Study: 38390815

Group type: EXPERIMENTAL
Intervention: Insulin resistance (assessed by the insulin sensitivity index)
Number of subjects: 2752

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP)
Number of subjects: 2752

Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP)
Number of subjects: 2752

Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP)
Number of subjects: 2752
Study: 38390822

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography-guided PCI
Number of subjects: 102
Study: 38391195

Group type: EXPERIMENTAL
Intervention: PED with Shield technology
Number of subjects: 543

Group type: COMPARATOR
Intervention: PED first-generation/PED Flex
Number of subjects: 543
Study: 38391202

Group type: EXPERIMENTAL
Intervention: Combination therapy using azacitidine and nivolumab (Aza/Nivo)
Number of subjects: 0
Study: 38391283

Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid treatment
Number of subjects: 43

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 43
Study: 38391282

Group type: EXPERIMENTAL
Intervention: Early invasive mechanical ventilation (EIMV)
Number of subjects: 4464

Group type: COMPARATOR
Intervention: Late invasive mechanical ventilation (LIMV)
Number of subjects: 4464
Study: 38391311

Group type: EXPERIMENTAL
Intervention: Quantitative US (QUS) radiomics data obtained after the 1st week of radiation therapy (RT)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: QUS analysis with gray-level co-occurrence matrix technique for textural analysis
Number of subjects: 55

Group type: COMPARATOR
Intervention: Radiation therapy (RT) with a total dose of 70 Gy in 33-35 fractions over 6-7 weeks
Number of subjects: 55
Study: 38392689

Group type: EXPERIMENTAL
Intervention: Ingestible medical device (MD) for collecting small intestinal liquids
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ingestible medical device (MD)
Number of subjects: 15
Study: 38393328

Group type: EXPERIMENTAL
Intervention: Benralizumab (30 mg)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Mepolizumab (300 mg)
Number of subjects: 140
Study: 38393676

Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel or ticagrelor for 5 days
Number of subjects: 86
Study: 38393694

Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ibrutinib+venetoclax
Number of subjects: 35
Study: 38393723

Group type: EXPERIMENTAL
Intervention: Belzutifan 120 mg once daily
Number of subjects: 61
Study: 38393755

Group type: EXPERIMENTAL
Intervention: Nursing educational intervention (4 sessions over 1 month, 1 week apart)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 116
Study: 38393754

Group type: EXPERIMENTAL
Intervention: Combustion-free nicotine alternatives (C-F NA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care with brief cessation advice (control group; arm A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Never smokers (reference group; arm C)
Number of subjects: 0
Study: 38393761

Group type: EXPERIMENTAL
Intervention: 16-week individualized and supervised exercise program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 200
Study: 38393773

Group type: EXPERIMENTAL
Intervention: MOON (serious video game intervention)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 152
Study: 38394048

Group type: EXPERIMENTAL
Intervention: Topical coconut-derived isosorbide diesters, dosage and duration not specified
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical sunflower seed oil-derived isosorbide diesters, dosage and duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control, dosage and duration not specified
Number of subjects: 0
Study: 38394113

Group type: EXPERIMENTAL
Intervention: Daily notification prompts for physical activity (PA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no prompts)
Number of subjects: 60